Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Jan Philipp Bewersdorf , Zhuoer Xie , Rafael Bejar , Uma Borate , Jacqueline Boultwood , Andrew M. Brunner , Rena Buckstein , Hetty E. Carraway , Jane E. Churpek , Naval G. Daver , Matteo Giovanni Della Porta , Amy E. DeZern , Pierre Fenaux , Maria E. Figueroa , Steven D. Gore , Elizabeth A. Griffiths , Stephanie Halene , Robert P. Hasserjian , Christopher S. Hourigan , Tae Kon Kim , Amer M. Zeidan
{"title":"Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)","authors":"Jan Philipp Bewersdorf , Zhuoer Xie , Rafael Bejar , Uma Borate , Jacqueline Boultwood , Andrew M. Brunner , Rena Buckstein , Hetty E. Carraway , Jane E. Churpek , Naval G. Daver , Matteo Giovanni Della Porta , Amy E. DeZern , Pierre Fenaux , Maria E. Figueroa , Steven D. Gore , Elizabeth A. Griffiths , Stephanie Halene , Robert P. Hasserjian , Christopher S. Hourigan , Tae Kon Kim , Amer M. Zeidan","doi":"10.1016/j.blre.2023.101072","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the first International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS) detailing recent advances in understanding the genetic landscape of MDS, including </span>germline<span> predisposition, epigenetic<span><span> and immune dysregulation<span>, the complexities of clonal hematopoiesis progression to MDS, as well as novel </span></span>animal models<span><span> of the disease. Connected to this progress is the development of novel therapies targeting specific molecular alterations, the innate immune system, and </span>immune checkpoint inhibitors. While some of these agents have entered </span></span></span></span>clinical trials (e.g., splicing modulators, IRAK1/4 inhibitors, anti-CD47 and anti-TIM3 antibodies, and cellular therapies), none have been approved for MDS. Additional preclinical and clinical work is needed to develop a truly individualized approach to the care of MDS patients.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"60 ","pages":"Article 101072"},"PeriodicalIF":6.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000334","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the first International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS) detailing recent advances in understanding the genetic landscape of MDS, including germline predisposition, epigenetic and immune dysregulation, the complexities of clonal hematopoiesis progression to MDS, as well as novel animal models of the disease. Connected to this progress is the development of novel therapies targeting specific molecular alterations, the innate immune system, and immune checkpoint inhibitors. While some of these agents have entered clinical trials (e.g., splicing modulators, IRAK1/4 inhibitors, anti-CD47 and anti-TIM3 antibodies, and cellular therapies), none have been approved for MDS. Additional preclinical and clinical work is needed to develop a truly individualized approach to the care of MDS patients.
期刊介绍:
Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.